84 completed, 41 recruiting, 33 unknown, 20 active not recruiting. 95 Not applicable, 51 Phase 2, 25 Phase 3, 15 Phase 1, 15 Phase 4.
Follow Treatment Resistant Depression: new trials by email Literature Review of Treatment Resistant Depression trials Research Report on Treatment Resistant Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG - Major Depressive Disorder (MDD), Treatment Resistant Depression | Not applicable | Not yet recruiting | Mayo Clinic | 60 | 2026-11-01 | 2026-10-16 |
| The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression. Aripiprazole Augmentation, Bupropion Augmentation - Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder | Phase 2 | Not yet recruiting | Washington University School of Medicine | 300 | 2026-10-01 | 2026-10-16 |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression Ketamine (0.5 mg/kg), Behavioural Activation Therapy - Treatment Resistant Depression, Major Depressive Disorder (MDD) | Phase 2 / Phase 3 | Not yet recruiting | The Royal's Institute of Mental Health Research | 60 | 2026-09-01 | 2026-09-03 |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2026-08-01 | 2026-03-30 |
| Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression Personalized iTBS, Non-Personalized iTBS, Sham iTBS - Major Depressive Disorder, Treatment Resistant Depression | Not applicable | Not yet recruiting | Stanford University | 80 | 2026-06-01 | 2026-04-14 |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression Ketamine, Oculus VR headset - Treatment Resistant Depression | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 31 | 2026-05-03 | 2026-08-13 |
| Mindfulness Engaged Neurostimulation for Depression (MEND II) Medi-TBS - Depression, Treatment Resistant Depression | Phase 2 | Recruiting | University of California, San Diego | 120 | 2026-05-01 | 2026-05-06 |
| ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder Repetitive transcranial magnetic stimulation (rTMS) - Depression - Major Depressive Disorder, Treatment Resistant Depression | Not applicable | Recruiting | Polytechnic Institute of Porto | 44 | 2026-03-15 | 2026-10-13 |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| Sustained Mood Improvement With Laughing Gas Exposure Inhalation of Nitrous oxide (Laughing gas) + intravenous saline, inhalation of %100 oxygen + intravenous midazolam - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Not yet recruiting | Women's College Hospital | 120 | 2026-02-01 | 2025-12-10 |
| Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement Vagus Nerve Stimulation - Treatment Resistant Depression | Not applicable | Not yet recruiting | Stanford University | 12 | 2026-01-01 | 2025-12-30 |
| Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-burst, Functional Imaging Guided, in the Treatment of Depression in Elderly Subjects With Cognitive Impairment transcranial magnetic stimulation by accelerated & high-dose theta-burst, functional imaging guided, i - Treatment Resistant Depression, Elderly Depression (≥65y.o.) | Not applicable | Not yet recruiting | Rennes University Hospital | 186 | 2025-12-15 | 2025-09-23 |
| Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression Psilocybin (drug), Placebo - Treatment Resistant Depression | Phase 2 | Recruiting | Beersheva Mental Health Center | 20 | 2025-12-01 | 2025-11-19 |
| Mental Health Mission Mood Disorder Cohort Study Depression - Major Depressive Disorder, Depression Bipolar | Not yet recruiting | University of Oxford | 2000 | 2025-10-01 | 2025-10-03 | |
| Characterizing Synaptic Density in Treatment Resistant Depression PET scans - Treatment Resistant Depression, Depression - Major Depressive Disorder | Recruiting | Unity Health Toronto | 45 | 2025-08-22 | 2026-09-15 | |
| Ketamine Augmentation of ECT in Treatment-Resistant Depression Ketamine Hydrochloride, Placebo - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Recruiting | Università Vita-Salute San Raffaele | 30 | 2025-07-10 | 2026-05-11 |
| Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients Treatment Resistant Depression | Recruiting | Senz | 120 | 2025-06-01 | 2026-07-15 | |
| Neurocardiac Predictors of Treatment Response to RTMS in Depression Repetitive Transcranial Magnetic Stimulation - Depression, Treatment Resistant Depression | Not applicable | Not yet recruiting | University of British Columbia | 110 | 2025-05-01 | 2024-12-24 |
| Multiple Ascending Dose Phase 1 Study of ALA-3000 ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR - Treatment Resistant Depression | Phase 1 | Completed | Alar Pharmaceuticals Inc. | 37 | 2025-04-21 | 2025-12-31 |
Showing 20 of 218. Sign in to see all of them.
Depressive Disorder, Treatment-Resistant (218) · Depressive Disorder, Major (82) · Depression (57) · Bipolar Disorder (17) · Depressive Disorder (16) · Mental Disorders (5) · Behavioral Symptoms (3) · Mood Disorders (3) · Suicidal Ideation (3) · Cognitive Dysfunction (2) · Suicide (2) · Aging, Premature (1) · Agnosia (1) · Alzheimer Disease (1) · Anhedonia (1)
Mood Disorders (215) · Mental Disorders (213) · Depressive Disorder (202) · Behavior (61) · Behavioral Symptoms (56) · Bipolar and Related Disorders (16) · Nervous System Diseases (8) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (5) · Self-Injurious Behavior (4) · Central Nervous System Diseases (3) · Neurocognitive Disorders (3) · Neurologic Manifestations (3) · Pathologic Processes (3) · Suicide (3)
Ketamine (27) · Psilocybin (18) · Transcranial Magnetic Stimulation (14) · Bupropion (5) · Deep Brain Stimulation (5) · Midazolam (5) · Lithium Carbonate (4) · Nitrous Oxide (4) · Transcranial Direct Current Stimulation (4) · Aripiprazole (3) · Esketamine (3) · Fluoxetine (3) · Nortriptyline (3) · Propofol (3) · Risperidone (3)
Stanford University (12) · Centre for Addiction and Mental Health (8) · Changping Laboratory (7) · Washington University School of Medicine (7) · Massachusetts General Hospital (6) · COMPASS Pathways (5) · University of Oxford (5) · Axsome Therapeutics, Inc. (4) · Unity Health Toronto (4) · University of California, San Diego (4) · LivaNova (3) · Mayo Clinic (3) · Sheppard Pratt Health System (3) · Soterix Medical (3) · Sunnybrook Health Sciences Centre (3)
United States (119) · Canada (37) · United Kingdom (16) · China (13) · Germany (10) · Denmark (9) · Australia (7) · Austria (6) · Netherlands (6) · Belgium (5) · France (5) · Spain (5) · Czechia (4) · Ireland (4) · Italy (4)
Hesheng Liu, Ph.D. (6) · David Spiegel, MD (4) · Nolan Williams, MD (4) · Eric Lenze, MD (3) · Helen Mayberg, MD (3) · Maurizio Fava, MD (3) · Scott Aaronson, MD (3) · Amit Anand, MD (2) · Charles Conway, MD (2) · Fengqiong Yu, MD (2) · Ishrat Husain, MBBS, MD (2) · Jonathan Gamble, MD (2) · Joshua D Rosenblat, MD, MSc (2) · Karim Ladha, MD (2) · Kevin Craig, M.D. (2)
PMID 34711062, PMID 39428602, PMID 10082232, PMID 10686270, PMID 12813115, PMID 15644873, PMID 15677610, PMID 15748841, PMID 16390886, PMID 16894061, PMID 17074942, PMID 17210143, PMID 17541113, PMID 18058285, PMID 18073775, PMID 18188442, PMID 18704022, PMID 18801471, PMID 19058788, PMID 19752841, PMID 19819427, PMID 20194822, PMID 20661246, PMID 20673547, PMID 20679587, PMID 20700385, PMID 21145043, PMID 21232924, PMID 21672551, PMID 22212598, PMID 22217452, PMID 22297150, PMID 22500865, PMID 22777127, PMID 22840761, PMID 22951236, PMID 22954259, PMID 23042884, PMID 23080404, PMID 23273725, PMID 23428794, PMID 23546169, PMID 23615187, PMID 23810357, PMID 23982301, PMID 24103187, PMID 24268616, PMID 24351501, PMID 25010396, PMID 25038867
271201100006I-0-27100007-1 (2), 5UH3NS103550 (2), 1UG3MH137353-01 (1), 2018 (1), 2023 (1), K01MH128663 (1), P20GM130452 (1), R01MH112815 (1), R01MH114966 (1), R01MH114970 (1), R01MH114980 (1), R01MH114981 (1), R01MH118388 (1), R21MH124759 (1), R61MH115927 (1)